Alcon (ALC) Stock

I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $118 per share, despite a minor guidance cut. Alcon's new product launches, including PRECISION7 and Systane Pro, are expected to drive significant growth in the vision segment. Alcon's surgical business, with a strong position in cataract surgery, is projected to grow 7% annually, driven by advanced technology and international expansion.

ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.

Eye-care group Alcon cut its 2024 forecasts and missed market expectations for third-quarter sales on Tuesday evening, as a soft U.S. market hit its surgical business.

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (TSX: ALC) today announced it will report its financial results for the three and nine months ended September 30, 2024 before market open on November 4, 2024. The Company's third quarter earnings release and full financial results will be available on the Company's website and on SEDAR. Algoma Central Corporation is a global provider of marine transportation that owns and operates dry and liquid bulk carriers, serving markets.

Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.

Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

Alcon CEO David Endicott comments on the company's second-quarter results.